New potential therapeutic targets have been identified for diabetic kidney disease (DKD) – the leading cause of kidney failure in the world – that could see patients treated with new gene and drug therapies preventing the disease’s progression into end stage kidney failure.
FDA finalizes 2014 guidance on informed consent in trials, with more updates coming soon
The FDA on Tuesday finalized guidance from 2014 to help sponsors, IRBs and investigators meet all of their informed consent requirements when it comes to
August 16, 2023